New hope for brain tumor patients: drug trial targets recurrent meningioma

NCT ID NCT07428616

Recruiting now Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 4 times

Summary

This phase 2 trial tests a drug called zanzalintinib in 100 people with meningioma that has returned or worsened after standard treatments like surgery or radiation. The goal is to see if the drug can shrink tumors or slow the disease. Participants take the drug by mouth, and researchers will monitor tumor response and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanzalintinib (a drug taken by mouth that targets tumor growth)
What this could lead to: If it works, this could offer a new treatment option for people with meningioma that has come back or worsened after standard therapies.
What could go wrong: This is a mid-stage trial with only 100 participants, so results may not apply to everyone. The drug may not shrink tumors or improve survival, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENINGIOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Baptist Health Miami Cancer Institute
RECRUITING

Miami, Florida, 33176, United States
Duke University
RECRUITING

Durham, North Carolina, 27710, United States
Inova Center for Personalized Health
RECRUITING

Fairfax, Virginia, 22031, United States
Mayo Clinic_Arizona
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic_Jacksonville
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic_Rochester
RECRUITING

Rochester, New York, 55905, United States
Memorial Sloan-Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
UT Health San Antonio Mays Cancer Center
RECRUITING

San Antonio, Texas, 78229, United States
UT MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
UW Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53792, United States
University of Alabama
RECRUITING

Birmingham, Alabama, 35294, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.